Brought to you by 
Vertex picks up global rights to two HCV candidates from Alios; Vertex ends HCV program
23 Jun 2014
Executive Summary
Alios BioPharma Inc. (antivirals) has licensed Vertex Pharmaceuticals Inc. (treatments for hepatitis C, cystic fibrosis, epilepsy, and other conditions) exclusive worldwide rights to the preclinical hepatitis C nucleotide analogues ALS2200 and ALS2158.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vertex picks up global rights to two HCV candidates from Alios; Vertex ends HCV program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice